linjc16/ctgov huggingface dataset:
Use of EtCO2 as a PaCO2 Predictor Under Non Invasive Ventilation (NIV) in Cases of Acute Hypercapnic Respiratory Failure

Study Overview
=================
Brief Summary
-----------------
In patients treated by Non invasive ventilation (NIV) due to acute hypercapnic respiratory failure, the interest of using the End-tidal Co2 measurement device Capnostream to evaluate PaCo2 and PaCo2 variations over time will be evaluated. Measurements will be done under normal expiration and under prolonged active and passive expiration maneuvers.

Official Title
-----------------
Use of EtCO2 and Prolonged Expiratory Maneuvers as a PaCO2 Predictor in Cases of Acute Hypercapnic Respiratory Failure

Conditions
-----------------
Hypercapnic Respiratory Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU patient equipped with arterial line NIV requirement Hypercapnia: PaCO2 > 45mmhg Exclusion Criteria: Severe hemodynamic instability Severe psychiatric disorders nasal lesions denied consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison between EtCO2,PaCO2 and PaCO2 variation under NIV during both spontaneous expiration and prolonged expiration | Comparison between EtCO2,PaCO2 and PaCO2 variation under NIV during both spontaneous expiration and prolonged expiration | Sixty minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute respiratory failure, Hypercapnia, Non invasive ventilation, End-tidal CO2
Determination of Normal Measures of Optic Nerve Sheath Diameter in Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measurement of optic nerve sheath diameter in children without intracranial pressure increase and determine the average optic nerve sheath diameters for healthy children.

Detailed Description
-----------------
The purpose of this study is to measurement of optic nerve sheath diameter in children without intracranial pressure increase and determine the average optic nerve sheath diameters for healthy children. For that, between 4 and 18 years old children will be selected. After taking of measurements, following parameters will be taken into account and measurements will be classified with those parameters . Age Gender Length (cm) Weight (kg) Waist Circumference (cm) Body Mass Index

Official Title
-----------------
Determination of Normal Measures of Optic Nerve Sheath Diameter in Children

Conditions
-----------------
Optic Papilla Edema

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Children without cerebral edema. Exclusion Criteria: • Children with cerebral edema.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for; Age Gender Weight Length Waist Circumference Body mass index|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of optic nerve sheath diameter | mm | 1-3 minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Optic nerve sheath diameter, average optic nerve sheath diameter for healthy children
Urotensin II and Vascular Tone in Cirrhosis

Study Overview
=================
Brief Summary
-----------------
This study looks at the iontophoresis of urotensin II in chronic liver disease patients.

Conditions
-----------------
Liver Diseases, Cirrhosis

Intervention / Treatment
-----------------
* Drug: urotensin II


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cirrhosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: urotensin II|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Liver Disease
Therapeutic Controlled Hypothermia in the Treatment of Neonates With Severe Necrotizing Enterocolitis

Study Overview
=================
Brief Summary
-----------------
Hypothesis: Controlled hypothermia to 33.5C for 48 hours reduces the severity of critical illness in neonates with severe necrotizing enterocolitis.

Official Title
-----------------
Therapeutic Controlled Hypothermia in the Treatment of Neonates With Severe Necrotizing Enterocolitis

Conditions
-----------------
Necrotizing Enterocolitis

Intervention / Treatment
-----------------
* Procedure: cooling blanket/mattress
* Procedure: Standard treatment of care at normothermia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: weight at diagnosis > 700 grams confirmed NEC (Bell's stage II or III) radiological evidence of pneumatosis coli systemic compromise as defined by increase in ventilation requirement and/or requiring inotopic support
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Standard treatment of care at normothermia<br>Control group: Standard treatment of care at normothermia | Procedure: Standard treatment of care at normothermia<br>* Standard treatment of care in 33.5C for 48 hours<br>|
| Experimental: cooling blanket/mattress<br>Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress | Procedure: cooling blanket/mattress<br>* Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in sequential organ failure assessment (SOFA) score | Difference in sequential organ failure assessment (SOFA) score at 5 days after intervention | 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Baseline time taken to establish full enteral feeds | Time to establish full enteral feeds and organ functional investigation and biomarkers at baseline, 24 hours post, 63 hours post and day 5 post intervention | 5 days | 
| Neurodevelopmental Assessment | Neurodevelopmental outcome with MRI at term corrected age and neurodevelopmental assessment at 3, 6,12 and 24 months and mortality data | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypothermia, cooling, necrotizing enterocolitis, NEC, neonates, preterm
Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy

Study Overview
=================
Brief Summary
-----------------
Temporal artery biopsy is a useful tool helping to the diagnosis of giant cell arteritis. However, other diagnoses might be associated with abnormal temporal artery biopsy. The purpose of this study is to describe the frequency of giant cell arteritis differential diagnoses with positive temporal artery biopsy.

Official Title
-----------------
Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy: a Monocentric Retrospective Study

Conditions
-----------------
Giant Cell Arteritis, Vasculitis

Intervention / Treatment
-----------------
* Diagnostic Test: temporal artery biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: positive artery biopsy between january 1st 2000 and july 25th 2019 Exclusion Criteria: orther vascular biopsy than temporal artery biospy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| positive temporal artery biopsy<br>all adult patients with significant inflammation shown on temporal artery biopsy | Diagnostic Test: temporal artery biopsy<br>* description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of giant cell arteritis and differential diagnoses |  | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
giant cell arteritis, temporal artery biopsy, vasculitis
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Study Overview
=================
Brief Summary
-----------------
This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso. A call-center will contact the patients directly at weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24 to review their dose and titration schedule. In addition to patient-reported dosing data, some patient demographic information, will be collected by the investigative site at Baseline.

Official Title
-----------------
A Patient Registry to Observe the Real-World Dosing and Titration of Tyvaso®

Conditions
-----------------
Pulmonary Arterial Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Are newly prescribed Tyvaso for the treatment of PAH and plan to initiate therapy Are willing and able to be contacted by the patient call center. Exclusion Criteria: Have previously received Tyvaso. Are currently enrolled in an interventional (non-FDA approved) PH clinical trial.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observe dose changes of Tyvaso over time |  | 6 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tyvaso, PAH
Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determine the tolerance of apoptotic autologous cells injection in subjects with active rheumatoid arthritis.

Official Title
-----------------
Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis

Conditions
-----------------
Arthritis, Rheumatoid

Intervention / Treatment
-----------------
* Biological: Autologous apoptotic cells injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a diagnosis of Rheumatoid arthritis Therapy failure with at least one biological agent from anti-TNF-alpha (etanercept, infliximab, adalimumab, certolizumab and golimumab; 3 months at optimal dose), anti-IL6 (tocilizumab; 3 months); T-cell costimulatory pathway inhibitor (abatacept; 3 months); anti-CD20 (rituximab; 6 months at optimal dose); Anti IL-1 (anakinra; 3 months) Disease Activity Score (DAS) DAS28 ≥ 3.2 Subject has provided written informed consent Exclusion Criteria: Pregnant or lactating women Inflammatory arthritis other than rheumatoid arthritis History of invasive cancer Immunodeficiency (HIV infection, Immunosuppressive therapy) Active bacterial or viral infections, in particular HCV or HBV. Surgery not older than 4 weeks. Unstable comorbidities: uncontrolled diabetes, heart disease, advanced renal or hepatic impairment. Contraindication to an apheresis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rheumatoid arthritis<br>Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0. | Biological: Autologous apoptotic cells injection<br>* cells injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerance of apoptotic cells injection | Side effects are taken into account to assess tolerance. | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Apoptotic cells
Orsiro™ Drug Eluting Stent in Routine Clinical Practice

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate effectiveness and safety of Orsiro™ Drug Eluting Stent in Routine Clinical Practice

Official Title
-----------------
Evaluation of Effectiveness and Safety of Orsiro™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Conditions
-----------------
Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: Orsiro™ Drug Eluting Stent group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20 and more Intervention with Orsiro™ Drug Eluting Stent Agreed with written informed consent form Exclusion Criteria: Intervention with Orsiro™ drug eluting coronary stent and other drug eluting stent at the same time Life expectancy of 1year and under Cardiac shock

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Orsiro™ Drug Eluting Stent<br> | Device: Orsiro™ Drug Eluting Stent group<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite event rate |  | 1YEAR | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ALL DEATH |  | 5YEAR | 
| CARDIAC DEATH |  | 5YEAR | 
| MYOCARDIAL INFARCTION |  | 5YEAR | 
| Composite event of death or myocardial infarction |  | 5YEAR | 
| Composite event of cardiac death or myocardial infarction |  | 5YEAR | 
| Target Vessel revascularization |  | 5YEAR | 
| Target Lesion revascularization |  | 5YEAR | 
| Stent thrombosis | stent thrombosis as classified by an Academic Research Consortium | 5YEAR | 
| Stroke |  | 5YEAR | 
| Procedural success | defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days. | 3day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Orsiro, Drug Eluting Stent, Routine Clinical Practice, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease
Characterize Differences in Force Patterns Used by Different Endoscopists and Trainee Endoscopists

Study Overview
=================
Brief Summary
-----------------
The study is to evaluate how doctors in training are different from very experienced doctors when using force to perform colonoscopy with a device that monitors the amount of force applied to the colonoscope during colonoscopy.

Detailed Description
-----------------
The study consists of two sequential observational studies designed to identify which instrument should be used to assess trainee performance and to quantify trainee skill development in performance of colonoscopy over the course of their training program.

Official Title
-----------------
Phase II Study of Evaluation of Handheld Colonoscopy Force Monitor by Expert and Trainee Endoscopists in the Performance of Colonoscopy

Conditions
-----------------
Compare Performance of Colonoscopists

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing diagnostic or screening colonoscopy ASA Class I or II All ethnic and racial groups will be included Able to comprehend, sign and date the written informed consent form (ICF) English is their primary language Exclusion Criteria: Chronic pathology that in the opinion of the endoscopist could interfere with the colonoscopy. Examples include: colonic stricture, poor preparation, obstructing tumor Specific pathology that would limit the extent of examination ASA class 3 or greater Pregnancy Vulnerable subjects. Students, nursing home residents, institutionalized patients, and those with psychological or physical incapacity

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Colonoscopy Force Monitoring demonstrates patterns of how doctors in training are different from very experienced doctors when they do colonoscopy. |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colonoscopy, Force, Monitor, Endoscopist, Trainee
Study of the Effectiveness of Osteopathic Manipulative Treatment in Pregnant Women

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether osteopathic manipulative treatment (OMT): decreases pain and improves physical functioning in women during the third trimester of pregnancy decreases complications during obstetrical delivery improves quality of life in the post-partum period

Detailed Description
-----------------
Women experience multiple changes in their anatomy and physiology during pregnancy that may cause pain and adversely affect quality of life. Additionally, about ten percent of women will experience signs and symptoms of pre-eclampsia or pre-term labor during their first pregnancy. Preliminary studies of osteopathic manipulative treatment (OMT) have demonstrated a decrease in pain during pregnancy, although the mechanisms responsible for this effect are unclear. Another theory is that osteopathic manipulative treatment (OMT) may help normalize sympathetic outflow, thereby minimizing pregnancy complications. A recently published retrospective study also suggests that pregnant women receiving osteopathic manipulative treatment (OMT) may be at lower risk for pre-term delivery and the presence of meconium during delivery.

Official Title
-----------------
Pilot Clinical Trial of Osteopathic Manipulative Treatment (OMT) in Pregnancy

Conditions
-----------------
Low Back Pain, Musculoskeletal Diseases, Pregnancy Complications

Intervention / Treatment
-----------------
* Procedure: Osteopathic manipulative treatment (OMT)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Third trimester pregnancy Exclusion Criteria: High risk pregnancy Previous use of chiropractic manipulation, osteopathic manipulative treatment (OMT), physical therapy, or therapeutic ultrasound during the current pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Osteopathic manipulative treatment (OMT)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analogue scale for pain, Roland-Morris Disability Questionnaire, and SF-12 Health Status Survey during third trimester of pregnancy and continuing six weeks post-partum |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of premature labor and delivery as well as obstetrical complications during delivery |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Randomized Controlled Trial, Pregnant Women